IMM60 and Pembrolizumab in Melanoma and NSCLC

Prior treatment

• Has had an allogeneic tissue/solid organ transplant
• Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable.

Other illness

• Another active malignancy within the past 2 years (Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder, or carcinoma in situ [e.g., breast carcinoma, cervical cancer in situ] that have undergone potentially curative therapy are not excluded. Also, prostate, breast, and neuroendocrine tumors that are stable on hormonal treatment for a period of 1 year or more without the need to adjust dose are not excluded.)
• History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• Participants with an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids (in dosing exceeding 10 mg daily of prednisone equivalent) or immunosuppressive agents.
• Participants who are known to be serologically positive for Hepatitis B, Hepatitis C, or human immunodeficiency virus.

Lab values

• Has the following cardiac conditions:
  • Corrected QT interval (QTc) > 450 ms
  • Uncontrolled hypertension with blood pressure (BP) > 160/100 despite treatment
  • Class II or greater heart failure as defined by the New York Heart Association
  • Myocardial infarction within 6 months or angina requiring nitrate therapy more than once a week

• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score 0 to 1
• Adequate organ function
• At least 1 lesion, not previously irradiated, that can be accurately measured on CT or MRI as defined by RECIST 1.1 criteria
• NSCLC cohorts: Histologically confirmed diagnosis of stage IV NSCLC
• NSCLC cohorts: Patients with adenocarcinoma histology must not have sensitizing epidermal growth factor receptor (EGFR) or ROS proto-oncogene 1 (ROS1) mutations or anaplastic lymphoma kinase (ALK) translocations
• NSCLC cohorts: Participants in NSCLC arms must have a PD-L1 assessment (PD-L1 immuno-histochemistry (IHC) 22C3 pharmDx)
• Melanoma cohorts: Unresectable stage III or IV, histologically confirmed diagnosis of cutaneous or unknown primary melanoma
• Melanoma cohorts: B-type Raf proto-oncogene (BRAF) mutation status available
• Male participants: Participant must agree to use contraception and refrain from sperm donation during the treatment period and for at least 120 days after the last dose of study intervention
• Female participants: Participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
  • Not a woman of childbearing potential (WOCBP)
  • A WOCBP who agrees to follow contraceptive guidance during the treatment period and for at least 6 months after the last dose of study intervention